欧洲泌尿外科学会非肌层浸润性膀胱癌(TaT1及原位癌)指南:2019年更新
本指南为欧洲泌尿外科学会(EAU)非肌层浸润性膀胱癌(NMIBC,TaT1及原位癌)的2019年更新版,涵盖临床表现、诊断与治疗推荐。诊断依赖膀胱镜及经尿道膀胱肿瘤电切术(TURB)或膀胱活检的组织学评估;按EORTC评分系统进行低、中、高危分层以指导辅助治疗;推荐对特定患者行二次TURB、即刻化疗灌注、BCG灌注或根治性膀胱切除术。
要点
- 诊断依赖膀胱镜及TURB或膀胱活检的组织学评估。
- 低危及部分中危患者推荐一次即刻化疗灌注。
- 高危患者推荐足量膀胱内BCG灌注1-3年。
核心结论
- 本简明版EAU指南提供NMIBC诊断与治疗的最新信息以供临床实践采用。
- 患者按低、中、高危分层对决定辅助膀胱内化疗或BCG灌注至关重要。
- BCG无应答肿瘤或进展风险最高的NMIBC应考虑手术切除膀胱。
研究设计与样本
- EAU指南2019年更新版,自2017年上一版发布以来每年对NMIBC指南全部领域进行广泛范围综述。
- 检索数据库包括Medline、EMBASE和Cochrane Libraries,并更新既往指南、分配证据级别与推荐等级。
- 推荐基于截至2018年底的当前文献,强调来自随机临床试验和Meta分析的高级数据。
主要发现
- Ta、T1和/或原位癌(CIS)统归为NMIBC。
- 乳头状病变中,完整的TURB对患者预后和正确诊断至关重要。
- 初始切除不完整、标本无肌层或检出T1肿瘤时,应在2-6周内行二次TURB。
- 可使用EORTC评分系统评估个体患者的复发和进展风险。
关键数值与推荐
- 低危肿瘤患者以及既往复发率低且预期EORTC复发评分<5的中危患者,推荐一次即刻化疗灌注。
- 中危肿瘤患者应接受1年足量膀胱内BCG免疫治疗或最长1年的化疗灌注。
- 高危肿瘤患者适合足量膀胱内BCG治疗1-3年。
- 进展风险最高的患者应考虑即刻根治性膀胱切除术。
- BCG无应答肿瘤推荐行膀胱切除术。
临床怎么用
- 诊断依靠膀胱镜及乳头状肿瘤TURB或CIS多点膀胱活检的组织学评估。
- 乳头状病变需完整TURB以保障预后和正确诊断。
- 初始切除不完整、标本无肌层或检出T1肿瘤时,应在2-6周内行二次TURB。
- 基于EORTC评分系统将患者分为低、中、高危以推荐辅助治疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: This overview presents the updated European Association of Urology (EAU) guidelines for non-muscle-invasive bladder cancer (NMIBC), TaT1, and carcinoma in situ (CIS). OBJECTIVE: To provide practical recommendations on the clinical management of NMIBC with a focus on clinical presentation and recommendations. EVIDENCE ACQUISITION: A broad and comprehensive scoping exercise covering all areas of the NMIBC guidelines has been performed annually since the last published version in 2017. Databases covered by the search included Medline, EMBASE, and the Cochrane Libraries. Previous guidelines were updated, and the level of evidence and grade of recommendation were assigned. EVIDENCE SYNTHESIS: Tumours staged as Ta, T1, and/or CIS are grouped under the heading of NMIBC. Diagnosis depends on cystoscopy and histological evaluation of the tissue obtained by transurethral resection (TURB) in papillary tumours or by multiple bladder biopsies in CIS. In papillary lesions, a complete TURB is essential for the patient's prognosis and correct diagnosis. Where the initial resection is incomplete, where there is no muscle in the specimen, or where a T1 tumour is detected, a second TURB should be performed within 2-6 wk. The risks of both recurrence and progression may be estimated for individual patients using the European Organisation for Research and Treatment of Cancer (EORTC) scoring system. Stratification of patients into low-, intermediate-, and high-risk groups is pivotal to the recommendation of adjuvant treatment. In patients with tumours presumed to be at a low risk and in those presumed to be at an intermediate risk with a low previous recurrence rate and an expected EORTC recurrence score of <5, one immediate chemotherapy instillation is recommended. Patients with intermediate-risk tumours should receive 1 yr of full-dose bacillus Calmette-Guérin (BCG) intravesical immunotherapy or instillations of chemotherapy for a maximum of 1 yr. In patients with high-risk tumours, full-dose intravesical BCG for 1-3 yr is indicated. In patients at the highest risk of tumour progression, immediate radical cystectomy should be considered. Cystectomy is recommended in BCG-unresponsive tumours. The extended version of the guidelines is available at the EAU website: https://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/. CONCLUSIONS: These abridged EAU guidelines present updated information on the diagnosis and treatment of NMIBC for incorporation into clinical practice. PATIENT SUMMARY: The European Association of Urology Non-muscle-invasive Bladder Cancer (NMIBC) Panel has released an updated version of their guidelines, which contains information on classification, risk factors, diagnosis, prognostic factors, and treatment of NMIBC. The recommendations are based on the current literature (until the end of 2018), with emphasis on high-level data from randomised clinical trials and meta-analyses. Stratification of patients into low-, intermediate-, and high-risk groups is essential for deciding appropriate use of adjuvant intravesical chemotherapy or bacillus Calmette-Guérin (BCG) instillations. Surgical removal of the bladder should be considered in case of BCG-unresponsive tumours or in NMIBCs with the highest risk of progression.
引用
- Babjuk M, Burger M, Compérat EM, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. Eur Urol. 2019. PMID: 31443960. doi:10.1016/j.eururo.2019.08.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。